title: Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.
abstract: We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer. Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.
authors.affiliation: 1 Department of Pharmacology and Toxicology, The University of Texas Medical Branch , Galveston, TX 77555.
authors.forename: Olga
authors.initials: O
authors.lastname: Zolochevska
authors.forename: Jayne
authors.initials: J
authors.lastname: Ellis
authors.forename: Sangram
authors.initials: S
authors.lastname: Parelkar
authors.forename: Delphine
authors.initials: D
authors.lastname: Chan-Seng
authors.forename: Todd
authors.initials: T
authors.lastname: Emrick
authors.forename: Jingna
authors.initials: J
authors.lastname: Wei
authors.forename: Igor
authors.initials: I
authors.lastname: Patrikeev
authors.forename: Massoud
authors.initials: M
authors.lastname: Motamedi
authors.forename: Marxa L
authors.initials: ML
authors.lastname: Figueiredo
mesh_terms: D001859:Bone Neoplasms / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D002454:Cell Differentiation / Q000187:drug effects; D018014:Gene Transfer Techniques; D006801:Humans; D064094:Interleukin-27 / Q000235:genetics / Q000627:therapeutic use*; D008297:Male; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics / Q000628:therapy*
chemical_list: D064094:Interleukin-27
references.citation: Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S148-57
references.pmid: 14600605
references.citation: Cancer Treat Res. 2004;118:311-39
references.pmid: 15043198
references.citation: Arthritis Rheum. 2010 Feb;62(2):402-13
references.pmid: 20112358
references.citation: J Immunol. 2008 May 15;180(10):6527-35
references.pmid: 18453571
references.citation: J Immunol. 2010 Mar 1;184(5):2348-54
references.pmid: 20139275
references.citation: J Urol. 2001 Dec;166(6):2023-31
references.pmid: 11696699
references.citation: Clin Cancer Res. 2010 Aug 15;16(16):4188-97
references.pmid: 20587591
references.citation: Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54
references.pmid: 17940447
references.citation: Mol Imaging. 2008 Sep-Oct;7(5):199-213
references.pmid: 19123990
references.citation: Mol Ther. 2007 Jun;15(6):1053-64
references.pmid: 17457317
references.citation: Curr Med Chem. 2010;17(29):3303-8
references.pmid: 20712574
references.citation: PLoS One. 2011;6(5):e19389
references.pmid: 21603655
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15047-52
references.pmid: 14657353
references.citation: J Immunol. 2004 Dec 15;173(12):7170-82
references.pmid: 15585838
references.citation: N Engl J Med. 2004 Apr 15;350(16):1655-64
references.pmid: 15084698
references.citation: Biomaterials. 2011 Mar;32(9):2432-44
references.pmid: 21215446
references.citation: Front Biosci (Schol Ed). 2012 Jan 01;4:988-1006
references.pmid: 22202104
references.citation: Cancer. 2000 Jun 15;88(12 Suppl):2989-94
references.pmid: 10898342
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1581-7
references.pmid: 9362425
references.citation: J Neurooncol. 1995;23(2):135-47
references.pmid: 7543940
references.citation: J Urol. 2008 Sep;180(3):1154-60
references.pmid: 18639279
references.citation: BJU Int. 2012 Dec;110(11 Pt B):E520-5
references.pmid: 22578070
references.citation: Hum Pathol. 2000 May;31(5):578-83
references.pmid: 10836297
references.citation: Clin Exp Metastasis. 2008;25(5):581-90
references.pmid: 18506587
references.citation: J Orthop Res. 2009 May;27(5):673-9
references.pmid: 19016539
references.citation: Osteoporos Int. 2011 Mar;22(3):931-42
references.pmid: 20480144
references.citation: Clin Prostate Cancer. 2002 Dec;1(3):145-52
references.pmid: 15046689
references.citation: Bone. 2011 Jan;48(1):141-51
references.pmid: 20685406
references.citation: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474
references.pmid: 22336790
references.citation: Am J Med. 1997 Aug;103(2):134-45
references.pmid: 9274897
references.citation: Bone. 2009 Feb;44(2):335-44
references.pmid: 19013264
references.citation: Hum Immunol. 2007 Dec;68(12):965-72
references.pmid: 18191724
references.citation: J Cell Physiol. 2013 May;228(5):1127-36
references.pmid: 23086758
references.citation: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5
references.pmid: 10097072
references.citation: Endocr Relat Cancer. 1999 Sep;6(3):333-47
references.pmid: 10516850
references.citation: Cancer Treat Rev. 2001 Jun;27(3):165-76
references.pmid: 11417967
references.citation: J Bone Miner Metab. 2007;25(5):277-85
references.pmid: 17704992
references.citation: Cancer Res. 2011 Aug 15;71(16):5387-92
references.pmid: 21676887
references.citation: Med Res Rev. 2012 Sep;32(5):1078-91
references.pmid: 21287572
references.citation: J Urol. 1997 Feb;157(2):439-44
references.pmid: 8996327
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1588-94
references.pmid: 9362426
references.citation: Eur J Immunol. 2012 Jun;42(6):1547-52
references.pmid: 22678908
references.citation: Mol Cell Endocrinol. 2011 Mar 30;335(2):126-34
references.pmid: 21238535
references.citation: Mol Reprod Dev. 2006 Aug;73(8):987-97
references.pmid: 16496417
references.citation: Hum Gene Ther. 2011 Dec;22(12):1537-50
references.pmid: 21801027
references.citation: BJU Int. 2000 Sep;86(4):449-52
references.pmid: 10971270
references.citation: Cancer Res. 2007 Aug 1;67(15):7450-7
references.pmid: 17671215
references.citation: Oral Oncol. 2009 Sep;45(9):e106-12
references.pmid: 19515604
references.citation: Cancer Res. 2004 Feb 1;64(3):1152-6
references.pmid: 14871851
references.citation: J Immunol. 2009 Aug 15;183(4):2397-406
references.pmid: 19620301
references.citation: J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
references.pmid: 15173273
references.citation: J Immunol. 2003 May 15;170(10):4886-90
references.pmid: 12734330
references.citation: Pharmacotherapy. 2012 Mar;32(3):274-84
references.pmid: 22392458
references.citation: Nat Rev Cancer. 2002 Aug;2(8):584-93
references.pmid: 12154351
references.citation: Prostate. 2011 Mar 1;71(4):353-67
references.pmid: 20812223
references.citation: Curr Opin Investig Drugs. 2008 Oct;9(10):1089-94
references.pmid: 18821471
references.citation: J Immunol. 2009 Apr 1;182(7):4328-38
references.pmid: 19299733
references.citation: J Urol. 2000 Oct;164(4):1248-53
references.pmid: 10992374